Typically, 85–90% of T1DM patients develop characteristic anti-insulin antibodies, antibodies against 65 kDa glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (1A-2), and zinc transporter 8 (ZNT8). The gene discussed is GAD2; the disease is type 1 diabetes mellitus.